Fresenius SE & Co KGaA
XETRA:FRE

Watchlist Manager
Fresenius SE & Co KGaA Logo
Fresenius SE & Co KGaA
XETRA:FRE
Watchlist
Price: 33.2 EUR 0.76%
Market Cap: 18.7B EUR
Have any thoughts about
Fresenius SE & Co KGaA?
Write Note

Fresenius SE & Co KGaA
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Fresenius SE & Co KGaA
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Fresenius SE & Co KGaA
XETRA:FRE
Accounts Receivables
€3.8B
CAGR 3-Years
-20%
CAGR 5-Years
-12%
CAGR 10-Years
-1%
F
Fresenius Medical Care AG & Co KGaA
XETRA:FME
Accounts Receivables
€4B
CAGR 3-Years
6%
CAGR 5-Years
2%
CAGR 10-Years
6%
Vita 34 AG
XETRA:V3V
Accounts Receivables
€16.1m
CAGR 3-Years
83%
CAGR 5-Years
40%
CAGR 10-Years
21%
E
Euroeyes International Eye Clinic Ltd
HKEX:1846
Accounts Receivables
HK$6.9m
CAGR 3-Years
15%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Synlab AG
XETRA:SYAB
Accounts Receivables
€397.6m
CAGR 3-Years
-9%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Fresenius Medical Care AG
XMUN:FME
Accounts Receivables
€4B
CAGR 3-Years
6%
CAGR 5-Years
2%
CAGR 10-Years
6%
No Stocks Found

Fresenius SE & Co KGaA
Glance View

Market Cap
18.7B EUR
Industry
Health Care

Fresenius SE & Co KGaA is a global healthcare group rooted in Germany, dedicated to providing high-quality medical services and products to patients worldwide. Founded in 1912, the company has grown into a diverse organization with a strong focus on life-saving therapies in renal care, hospital services, and pharmaceutical manufacturing. With its subgroups—Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed—the company operates across different segments that collectively support its vision of enhancing patient outcomes, improving quality of care, and meeting the increasing demand for healthcare services in an aging global population. By leveraging an extensive network of healthcare facilities, innovative product pipelines, and a commitment to sustainability, Fresenius positions itself as a leader in the dynamic healthcare landscape. For investors, Fresenius SE & Co KGaA represents an opportunity to engage with a stable yet growth-oriented enterprise. The company has consistently demonstrated resilience, even amidst market fluctuations, reflecting a strong financial foundation and strategic leadership. With the global healthcare market projected to expand, driven by an increase in chronic diseases and the need for advanced medical solutions, Fresenius is well-poised to capture significant market share. Its focus on innovation, particularly in personalized medicine and digital health, underscores a forward-thinking approach that aligns with evolving patient needs. As a long-term investment option, Fresenius' commitment to enhancing healthcare accessibility and efficiency not only offers the potential for financial returns but also contributes positively to global health outcomes, making it a compelling choice for investors looking for a balance of impact and profit.

FRE Intrinsic Value
70.85 EUR
Undervaluation 53%
Intrinsic Value
Price

See Also

What is Fresenius SE & Co KGaA's Accounts Receivables?
Accounts Receivables
3.8B EUR

Based on the financial report for Sep 30, 2024, Fresenius SE & Co KGaA's Accounts Receivables amounts to 3.8B EUR.

What is Fresenius SE & Co KGaA's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
-1%

Over the last year, the Accounts Receivables growth was -8%. The average annual Accounts Receivables growth rates for Fresenius SE & Co KGaA have been -20% over the past three years , -12% over the past five years , and -1% over the past ten years .

Back to Top